PolyPeptide Group
PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six cGMP-certified facilities in Europe, the U.S. and India. PolyPeptide Group AG’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.
Shared 1 month ago
426 views
Shared 4 months ago
275 views
Shared 10 months ago
364 views
Shared 10 months ago
185 views
Shared 10 months ago
135 views
Shared 10 months ago
120 views
Shared 1 year ago
449 views
Shared 1 year ago
557 views
Shared 1 year ago
1.1K views
Shared 1 year ago
358 views
Shared 2 years ago
645 views
Shared 2 years ago
635 views
Shared 2 years ago
970 views
Shared 2 years ago
3.1K views
Shared 2 years ago
300 views
